Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Macrolide antibiotics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Macrolide antibiotics. Displaying page 1 of 1.
    EudraCT Number: 2019-004178-24 Sponsor Protocol Number: 1704 Start Date*: 2020-06-13
    Sponsor Name:Amphia
    Full Title: Defining long-term macrolide maintenance therapy in COPD: a single center randomized controlled trial:
    Medical condition: Chronic obstructive pulmonary disease COPD
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004143-11 Sponsor Protocol Number: 33103 Start Date*: 2008-12-17
    Sponsor Name:The University of Nottingham
    Full Title: Are macrolide antibiotics effective in chronic idiopathic cough?
    Medical condition: idiopathic chronic cough, defined as cough with no identifiable cause and which has been present for at least 2 monhs.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011224 Cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000247-58 Sponsor Protocol Number: PKZW-NZW201301 Start Date*: 2013-09-30
    Sponsor Name:KU Leuven Departement Ontwikkeling en Regeneratie
    Full Title: Pharmacokinetics of drugs used by pregnant women (paracetamol/macrolide antibiotics): in vivo pharmacokinetic study of pregnant versus non-pregnant women.
    Medical condition: 1) Pregnant women who, due to medical indication, need to take one of the experimental drugs (paracetamol, azithromycin or erythromycin) in the second or third trimester of there pregnancy 2) The s...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008314-40 Sponsor Protocol Number: BAYq3939/12429 Start Date*: 2009-06-22
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002792-34 Sponsor Protocol Number: Bronch Start Date*: 2014-02-26
    Sponsor Name:University Hospitals Leicester NHS Trust
    Full Title: Phenotyping bronchiectasis based on aetiology, exacerbation characteristics and response to erythromycin.
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002533-32 Sponsor Protocol Number: INS1007-201 Start Date*: 2018-03-22
    Sponsor Name:Insmed Incorporated
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 We...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) ES (Completed) NL (Completed) BG (Completed) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003077-42 Sponsor Protocol Number: CE01-204 Start Date*: 2015-02-06
    Sponsor Name:Imperial College, London
    Full Title: A single-centre, double-blind, randomised, placebo-controlled crossover study to evaluate the effect of solithromycin on airway inflammation in male and female patients with chronic obstructive pul...
    Medical condition: Chronic Obstructive Pulmonary Disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000471-20 Sponsor Protocol Number: RIPH_2019_01 Start Date*: 2020-11-30
    Sponsor Name:CH Tourcoing
    Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la...
    Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10065011 Prosthesis related infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004109-28 Sponsor Protocol Number: GA1211 Start Date*: 2013-01-18
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A randomised, 4 way crossover, double blind, placebo controlled pilot study in patients with reflux symptoms, to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Mint ’ us...
    Medical condition: This study assesses suppression of gastro-oesophageal reflux of Gaviscon in patients with gastro-oesophageal reflux disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002653-35 Sponsor Protocol Number: R668-AD-1424 Start Date*: 2016-01-14
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolera...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BE (Completed) GB (Completed) NL (Completed) SK (Completed) AT (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000728-41 Sponsor Protocol Number: 06/02-29 jan'07 Start Date*: 2008-09-12
    Sponsor Name:Maastro clinic
    Full Title: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer
    Medical condition: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy with locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038050 Rectal cancer stage III PT
    9.1 10038051 Rectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002166-40 Sponsor Protocol Number: RD.06.SPR.201591 Start Date*: 2021-11-18
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis with Inadequate Response to or for Whom C...
    Medical condition: Moderate-to-Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) LV (Completed) ES (Ongoing) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:49:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA